Treatment of rhinosinusitis with nasal polyposis with dupilumab and mepolizumab: A randomized, multi-centre, head-to-head comparison in real-world Danish patients

Chronic rhinosinusitis with nasal polyposis

Co-primary endpoint 1: Change in nasal polyp score (NPS) at 24 weeks, Co-primary endpoint 2: Change in SNOT-22 score at 24 weeks

Change in loss of smell (Proportion with SSIT-16 improved to >8), Improvement in asthma (measured by proportion with ACQ>0.5), Improvement on visual analog scale measuring impact on quality of life of CRSwNP, Tympanometry - proportion with change from B-curve to A or C curve., Expired Nitrous oxide (FeNO) - proportion with less than 25 ppb, Improvement in subjective smell function by visual analog scale, Improvement in aspirin-exacerbated-respiratory-intolerance (AERD) measured by visual analog scale., Improvement in NPS at 52 weeks, Improvement in SNOT-22 at 52 weeks, Proportion meeting the response criteria set by the Danish Medicines council, Proportion of subjects needing rescue treatment (systemic corticosteroids or sinus surgery), Change in Nasal Congestion Score (NCS), Chang in radiologic sinus opacification (Lund-Mackey score), Change in FEV1

No related papers found yet.

Papers published before 2008-02-04 may not appear yet. Historical indexing is in progress.

Denmark